Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Malignant Thymoma Clear all
Not listed Phase 2 Interventional Results available

Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

NCT02364076
View directory record Official record
Conditions
Thymic Carcinoma, Thymus Neoplasms, Thymus Cancer
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Jun 25, 2026, 10:43 AM EDT
Recruiting Phase 1 Interventional

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

NCT03295227
View directory record Official record
Conditions
Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8, Stage IIIB Thymoma AJCC v8, Stage IV Thymoma AJCC v8, Stage IVA Thymoma AJCC v8, Stage IVB Thymoma AJCC v8, Unresectable Thymic Carcinoma
Interventions
Pembrolizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 2 Interventional

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

NCT00003283
View directory record Official record
Conditions
Thymoma and Thymic Carcinoma
Interventions
octreotide acetate, prednisone
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
24
States / cities
Palo Alto, California • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jun 25, 2026, 10:43 AM EDT
Terminated Phase 2 Interventional Results available

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

NCT04925947
View directory record Official record
Conditions
Thymic Carcinoma
Interventions
KN046
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jun 25, 2026, 10:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

NCT01100944
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma
Interventions
PXD101with cisplatin+doxorubicin+cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

NCT03583086
View directory record Official record
Conditions
Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
Interventions
Vorolanib, Nivolumab
Drug · Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Palo Alto, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jun 25, 2026, 10:43 AM EDT
Completed No phase listed Observational

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430
View directory record Official record
Conditions
Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 25, 2026, 10:43 AM EDT
Active, not recruiting Phase 2 Interventional

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

NCT03076554
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma
Interventions
Avelumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

NCT01364727
View directory record Official record
Conditions
Thymoma, Thymus Cancer, Thymic Carcinoma
Interventions
Amrubicin
Drug
Lead sponsor
Heather Wakelee
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Stanford, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

NCT02629419
View directory record Official record
Conditions
Candidiasis, Chronic Mucocutaneous
Interventions
Amphotericin B
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 2 Interventional

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

NCT00003662
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Thymic Carcinoma
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
15
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Jun 25, 2026, 10:43 AM EDT
Terminated Phase 2 Interventional Results available

Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

NCT01301391
View directory record Official record
Conditions
Malignant Thymoma
Interventions
Milciclib Maleate
Drug
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Jun 25, 2026, 10:43 AM EDT
Terminated Phase 2 Interventional Results available

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

NCT02062632
View directory record Official record
Conditions
Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma, Mesothelioma, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Pleura, Metastatic Malignant Neoplasm in the Spinal Cord, Non-Small Cell Lung Carcinoma, Sarcoma, Small Cell Lung Carcinoma, Thymic Carcinoma, Thymoma, Thyroid Gland Carcinoma
Interventions
Doxepin Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy

NCT00965250
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma, Thymic Carcinoid, Thymic Neuroendocrine Tumors
Interventions
IMC-12
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Jun 25, 2026, 10:43 AM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

NCT01025089
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA
Interventions
Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
8
States / cities
Duarte, California • Basking Ridge, New Jersey • Commack, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

NCT03102320
View directory record Official record
Conditions
Neoplasms
Interventions
Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

NCT03694002
View directory record Official record
Conditions
Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma, Recurrent Thymic Carcinoma, Unresectable Thymic Carcinoma
Interventions
Carboplatin, Paclitaxel, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
254
States / cities
Anchorage, Alaska • Kingman, Arizona • Hot Springs, Arkansas + 153 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 2 Interventional

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

NCT00024076
View directory record Official record
Conditions
Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
Interventions
radiofrequency ablation
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

NCT00198133
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma
Interventions
Premetrexed (Alimta)
Drug
Lead sponsor
Patrick Joseph Loehrer Sr.
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Not applicable Interventional

Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers

NCT04662645
View directory record Official record
Conditions
Caregiver, Malignant Pleural Neoplasm, Metastatic Thymic Carcinoma, Recurrent Lung Carcinoma, Recurrent Thymic Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Palliative Therapy, Questionnaire Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

NCT03517488
View directory record Official record
Conditions
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
Interventions
XmAb20717
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jun 25, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies

NCT00921739
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Small Cell Lung Cancer, Thymoma, Thymus Neoplasms
Interventions
Esophageal sparing IMRT
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Jun 25, 2026, 10:43 AM EDT
Completed No phase listed Observational

Radiation Therapy and Cardiac Enzymes

NCT00777751
View directory record Official record
Conditions
Tumor
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Jun 25, 2026, 10:43 AM EDT